Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

Orthofix Medical Inc. develops, produces, and markets medical devices. The Company offers spine fixation, biological, and other orthopedic and spine solutions. Orthofix Medical serves the healthcare sector worldwide
Website: orthofix.com



Growth: Pretty weak revenue growth rate 8.0%, there is slowdown compared to average historical growth rates 22.9%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of -47.9%

Profitability: LTM EBITDA margin is negative, -4.6%. On average the margin is improving steadily. Gross margin is high, +68.3%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.06 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 0.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 15.9% higher than minimum and 50.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.2x by EV / Sales multiple , the company can be >100% undervalued

Insiders: For the last 3 months insiders bought company shares on $3.5 mln (0.829% of cap.)

Key Financials (Download financials)

Ticker: OFIX
Share price, USD:  (-13.8%)10.52
year average price 13.41  


year start price 12.54 2025-08-06

max close price 16.23 2025-10-22

min close price 9.08 2026-06-22

current price 10.96 2026-08-05
Common stocks: 38 020 000

Dividend Yield:  0.0%
EV / Sales: 0.6x
Margin (EBITDA LTM / Revenue): -4.6%
Fundamental value created in LTM:
Market Cap ($m): 464
Net Debt ($m): 0
EV (Enterprise Value): 464
Price to Book: 1.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-11-04seekingalpha.com

Orthofix Medical Inc. (OFIX) Q3 2025 Earnings Call Prepared Remarks Transcript

2025-09-04globenewswire.com

ORTHOFIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Orthofix Medical Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

2025-08-05seekingalpha.com

Orthofix Medical Inc. (OFIX) Q2 2025 Earnings Call Transcript

2025-05-06seekingalpha.com

Orthofix Medical Inc. (OFIX) Q1 2025 Earnings Call Transcript

2025-05-06zacks.com

Orthofix (OFIX) Reports Q1 Loss, Tops Revenue Estimates

2025-02-25zacks.com

Orthofix (OFIX) Q4 Earnings Lag Estimates

2025-02-17businesswire.com

Orthofix to Participate in the Canaccord Genuity 2025 Musculoskeletal Conference

2024-12-04accesswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Orthofix Medical Inc. (OFIX) Investors to Inquire about Securities Investigation

2024-11-10seekingalpha.com

Orthofix Medical Inc. (OFIX) Q3 2024 Earnings Call Transcript

2024-11-03globenewswire.com

OFIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Orthofix Medical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624
fillingDate 2025-11-04 2025-08-05 2024-11-07 2024-08-06 2024-05-07 2023-11-08 2023-08-08 2023-05-09 2022-11-03
acceptedDate 2025-11-04 09:01:22 2025-08-05 07:05:06 2025-02-25 07:08:51 2024-11-07 07:08:04 2024-08-06 07:08:06 2024-05-07 08:06:54 2024-03-05 16:06:47 2023-11-08 16:15:53 2023-08-08 16:28:12 2023-05-09 16:21:52 2023-03-06 16:11:56 2022-11-03 07:13:25 2022-02-25 08:21:26 2021-02-26 08:37:29
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 206M 203M 799M 197M 199M 189M 747M 184M 187M 175M 461M 114M 464M 407M
costOfRevenue 57M 64M 254M 62M 68M 66M 260M 64M 67M 65M 124M 31M 115M 102M
grossProfit 149M 140M 546M 135M 130M 123M 486M 120M 120M 110M 337M 83M 350M 305M
grossProfitRatio 0.722 0.687 0.687 0.657 0.652 0.651 0.639 0.63 0.732
researchAndDevelopmentExpenses 15M 16M 74M 17M 18M 19M 80M 19M 19M 23M 49M 12M 50M 39M
generalAndAdministrativeExpenses 0 0 533M 34M 34M 32M 145M 27M 34M 49M 80M 19M 69M 68M
sellingAndMarketingExpenses 0 0 0 97M 100M 100M 386M 95M 99M 94M 229M 55M 221M 204M
sellingGeneralAndAdministrativeExpenses 148M 136M 533M 130M 134M 132M 530M 122M 133M 143M 309M 75M 291M 272M
otherExpenses 3M 3M 24M 7M -3M -1M 15M -2M -20 000 676 000 -7M 2M 18M -499 000
operatingExpenses 166M 156M 631M 154M 152M 151M 625M 141M 157M 166M 350M 89M 358M 311M
costAndExpenses 223M 219M 884M 216M 220M 217M 886M 205M 225M 231M 474M 119M 473M 413M
interestIncome 0 0 0 0 0 0 0 2M 1M 0 0 0 0 0
interestExpense 5M 4M 30M 5M 5M 5M 9M 2M 1M 1M 1M 277 000 2M 2M
depreciationAndAmortization 15M 18M 60M 17M 14M 15M 61M 14M 15M 676 000 32M 5M 33M 34M
ebitda -3M 8M -34M -5M -13M -13M -79M -23M -23M -55M 16M -357 000 21M 36M
ebitdaratio -0.015 0.038 -0.024 -0.039 -0.071 -0.126 -0.123 -0.313 -0.003
operatingIncome -17M -16M -85M -19M -22M -28M -139M -24M -37M -56M -13M -5M -8M -6M
operatingIncomeRatio -0.083 -0.079 -0.096 -0.109 -0.149 -0.133 -0.196 -0.317 -0.047
totalOtherIncomeExpensesNet -5M 2M -39M -8M -7M -7M -10M -6M 1M -5M -4M -4M -5M 6M
incomeBeforeTax -22M -14M -124M -27M -32M -35M -149M -28M -38M -60M -18M -9M -13M -368 000
incomeBeforeTaxRatio -0.108 -0.07 -0.135 -0.163 -0.186 -0.154 -0.203 -0.344 -0.082
incomeTaxExpense 533 000 -142 000 2M 751 000 1M 851 000 3M 472 000 2M 611 000 2M 1M 25M -3M
netIncome -23M -14M -126M -27M -33M -36M -151M -29M -39M -61M -20M -11M -38M 3M
netIncomeRatio -0.111 -0.069 -0.139 -0.168 -0.191 -0.157 -0.211 -0.348 -0.094
eps -0.57 -0.36 -3.3 -0.71 -0.88 -0.95 -4.12 -0.77 -1.07 -1.71 -0.98 -0.53 -1.95 0.13
epsdiluted -0.57 -0.36 -0.71 -0.88 -0.95 -0.77 -1.07 -1.71 -0.53
weightedAverageShsOut 40M 40M 38M 38M 38M 38M 37M 37M 37M 36M 20M 20M 20M 19M
weightedAverageShsOutDil 40M 40M 38M 38M 38M 38M 37M 37M 37M 36M 20M 20M 20M 19M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-25 2024-03-05 2023-03-06 2022-02-25 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -30M -9M -1M -2M -2M
ebit -94M -140M -16M -12M 2M
nonOperatingIncomeExcludingInterest 10M 938 000 3M 3M -8M
netIncomeFromContinuingOperations -126M -151M -20M -38M 3M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -126M -151M -20M -38M 3M
epsDiluted -3.3 -4.12 -0.98 -1.95 0.13

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624
fillingDate 2025-11-04 2025-08-05 2024-11-07 2024-08-06 2024-05-07 2023-11-08 2023-08-08 2023-05-09 2022-11-03
acceptedDate 2025-11-04 09:01:22 2025-08-05 07:05:06 2025-02-25 07:08:51 2024-11-07 07:08:04 2024-08-06 07:08:06 2024-05-07 08:06:54 2024-03-05 16:06:47 2023-11-08 16:15:53 2023-08-08 16:28:12 2023-05-09 16:21:52 2023-03-06 16:11:56 2022-11-03 07:13:25 2022-02-25 08:21:26 2021-02-26 08:37:29
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 66M 66M 83M 30M 29M 29M 33M 34M 38M 50M 51M 52M 88M 96M
shortTermInvestments 0 0 0 0 0 1M 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 66M 66M 83M 30M 29M 29M 33M 34M 38M 50M 51M 52M 88M 96M
netReceivables 131M 130M 135M 125M 125M 126M 128M 114M 112M 113M 83M 76M 79M 72M
inventory 174M 173M 189M 206M 210M 219M 222M 222M 222M 222M 100M 100M 83M 85M
otherCurrentAssets 23M 28M 26M 26M 24M 25M 37M 24M 27M 25M 22M 19M 0 530 000
totalCurrentAssets 394M 396M 433M 386M 386M 399M 420M 394M 399M 410M 256M 247M 270M 270M
propertyPlantEquipmentNet 154M 154M 140M 147M 173M 177M 159M 153M 141M 137M 58M 58M 59M 64M
goodwill 195M 195M 195M 195M 195M 195M 195M 195M 192M 203M 71M 71M 71M 84M
intangibleAssets 76M 79M 99M 105M 108M 113M 117M 121M 126M 122M 47M 48M 53M 61M
goodwillAndIntangibleAssets 271M 274M 294M 299M 303M 308M 312M 316M 318M 325M 119M 119M 124M 145M
longTermInvestments 0 0 0 0 11M 5M 0 6M 6M 0 0 0 0 0
taxAssets 0 0 0 0 -11M -5M 0 -6M -6M 0 0 2M 2M 25M
otherNonCurrentAssets 14M 13M 26M 35M 20M 22M 33M 43M 44M 45M 26M 25M 22M 22M
totalNonCurrentAssets 438M 441M 460M 482M 496M 507M 505M 512M 502M 507M 203M 203M 207M 255M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 833M 837M 893M 868M 882M 906M 925M 906M 901M 917M 459M 450M 477M 526M
accountPayables 50M 45M 49M 47M 50M 57M 58M 53M 51M 46M 28M 28M 26M 23M
shortTermDebt 4M 4M 0 7M 5M 7M 1M 693 000 4M 664 000 0 638 000 0 0
taxPayables 0 0 8M 0 0 0 8M 0 0 0 7M 0 5M 6M
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0 2M 0 0
otherCurrentLiabilities 105M 99M 7M 108M 100M 86M 1 000 000 99M 87M 91M 0 47M 22M 25M
totalCurrentLiabilities 160M 148M 169M 162M 156M 151M 165M 153M 142M 138M 84M 78M 106M 104M
longTermDebt 201M 201M 157M 130M 147M 115M 93M 89M 88M 64M 0 19M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 30M 30M 47M 50M 33M 70M 50M 49M 32M 51M 19M 8M 14M 43M
totalNonCurrentLiabilities 230M 230M 222M 180M 180M 185M 161M 138M 119M 115M 38M 38M 34M 65M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 43M 48M 23M 19M 35M 35M 23M 19M 41M 20M 22M 20M 24M 25M
totalLiabilities 390M 379M 390M 342M 336M 336M 327M 290M 261M 253M 122M 116M 140M 169M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 4M 4M 4M 4M 4M 4M 4M 4M 4M 4M 2M 2M 2M 2M
retainedEarnings -366M -343M -276M -247M -220M -186M -150M -128M -99M -60M 1M 8M 21M 59M
accumulatedOtherComprehensiveIncomeLoss 634 000 908 000 -4M -902 000 -3M -660 000 -1M -2M -108 000 -946 000 -1M -5M 0 3M
othertotalStockholdersEquity 804M 797M 770M 765M 753M 742M 736M 721M 328M
totalStockholdersEquity 442M 458M 503M 526M 546M 570M 599M 615M 640M 664M 337M 334M 337M 357M
totalEquity 442M 458M 503M 526M 546M 570M 599M 615M 640M 664M 337M 334M 337M 357M
totalLiabilitiesAndStockholdersEquity 833M 837M 868M 882M 906M 906M 901M 917M 450M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 833M 837M 893M 868M 882M 906M 925M 906M 901M 917M 459M 450M 477M 526M
totalInvestments 0 0 0 0 11M 6M 0 6M 6M 0 0 0 0 0
totalDebt 204M 205M 180M 137M 156M 157M 117M 89M 92M 65M 22M 20M 24M 25M
netDebt 139M 139M 96M 107M 127M 128M 84M 56M 54M 15M -29M -32M -64M -71M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-25 2024-03-05 2023-03-06 2022-02-25 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 135M 128M 83M 79M 72M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 20M 17M
totalPayables 67M 73M 39M 34M 33M
otherPayables 18M 15M 11M 8M 10M
accruedExpenses 90M 86M 43M 45M 43M
capitalLeaseObligationsCurrent 5M 4M 2M 4M 3M
capitalLeaseObligationsNonCurrent 18M 19M 19M 20M 22M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 780M 746M 335M 314M 292M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX OFIX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624 884 624
fillingDate 2025-11-04 2025-08-05 2024-11-07 2024-08-06 2024-05-07 2023-11-08 2023-08-08 2023-05-09 2022-11-03
acceptedDate 2025-11-04 09:01:22 2025-08-05 07:05:06 2025-02-25 07:08:51 2024-11-07 07:08:04 2024-08-06 07:08:06 2024-05-07 08:06:54 2024-03-05 16:06:47 2023-11-08 16:15:53 2023-08-08 16:28:12 2023-05-09 16:21:52 2023-03-06 16:11:56 2022-11-03 07:13:25 2022-02-25 08:21:26 2021-02-26 08:37:29
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -23M -14M -126M -27M -33M -36M -151M -29M -39M -61M -20M -11M -38M 3M
depreciationAndAmortization 15M 18M 76M 20M 14M 15M 61M 14M 15M 14M 32M 8M 33M 34M
deferredIncomeTax 0 -433 000 2M 325 000 767 283 408 000 579 000 333 000 436 000 379 000 314 000 -215 000 24M 11M
stockBasedCompensation 7M 8M 32M 7M 10M 9M 36M 6M 13M 13M 18M 5M 15M 16M
changeInWorkingCapital 5M -10M -19M 26M -5M -21M -54M -8M -13M -20M -29M -3M -18M 20M
accountsReceivables -2M 3M -10M 591 000 -105 837 813 000 -10M -3M 823 000 5M -7M 259 000 -7M 13M
inventory -4M -7M -6M 28M -2M -7M -58M -15M -16M -17M -18M -4M 619 000 -873 000
accountsPayables 0 -7M -6M -4M -7M -820 000 9M 2M 5M -4M 2M -3M 4M 3M
otherWorkingCapital 10M 58 000 1M 2M 3M -14M 6M 8M -2M -4M -7M 4M -16M 5M
otherNonCashItems 9M 11M 61M -14M 69M 60M 63M 16M 18M 19M -13M -371 000 2M -9M
netCashProvidedByOperatingActivities 12M 12M 26M 12M 9M -19M -46M 477 000 -6M -34M -12M -1M 18M 74M
investmentsInPropertyPlantAndEquipment -10M -7M -35M 20M -10M -11M -62M -22M -13M -12M -23M -6M -20M -17M
acquisitionsNet 0 0 0 0 0 0 29M -13 233 30M 29M -2M 0 0 -18M
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 -2M -10M
salesMaturitiesOfInvestments 0 0 7M 0 0 0 0 0 0 0 126 000 0 0 17M
otherInvestingActivites 10000 12 000 -26M 199.847 -50 000 13 233 -30M -500 000 84 000
netCashUsedForInvestingActivites -10M -7M -6M -10M -11M -22M -13M 17M -5M
debtRepayment -189 000 -187 000 -179 000 -174 000 -25M -163 000 -160 000 -27M -150 000
commonStockIssued 0 3M 120 000 3M 0 -1069.259 2M 0 0
commonStockRepurchased -9000 0 0 0 0 -2M 0 -167 000 -1M 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 -1M 0 0
otherFinancingActivites -5M -178 000 -2M -3M -3M 19M 6M 43M -102 000
netCashUsedProvidedByFinancingActivities -5M 3M -2M 138 354 21M 18M 6M 16M -252 000
effectOfForexChangesOnCash -99 000 1M -938 000 335 000 -91 000 -284 000 619 000 -329 000 166 000 221 000 -997 000 -887 000 -815 000 1M
netChangeInCash -3M 8M 48M 4M -598 000 -8M -13M -4M -12M -732 000 -37M -8M -9M 26M
cashAtEndOfPeriod 66M 69M 86M 33M 29M 29M 38M 34M 38M 50M 51M 52M 88M 97M
cashAtBeginningOfPeriod 69M 60M 38M 29M 29M 38M 51M 38M 50M 51M 88M 60M 97M 70M
operatingCashFlow 12M 12M 26M 12M 9M -19M -46M 477 000 -6M -34M -12M -1M 18M 74M
capitalExpenditure -10M -7M -35M -6M -10M -11M -62M -22M -13M -12M -23M -6M -20M -17M
freeCashFlow 2M 5M -9M 6M -611 517 -29M -108M -22M -18M -46M -35M -7M -1M 57M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-25 2024-03-05 2023-03-06 2022-02-25 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -100 000 -500 000 0 -1M -24M
netCashProvidedByInvestingActivities -28M -33M -25M -23M -52M
netDebtIssuance 54M 68M -3M -537 000 -323 000
longTermNetDebtIssuance 54M 68M -3M -537 000 -323 000
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 6M 5M 4M 9M 8M
netCommonStockIssuance 6M 5M 4M 9M 8M
commonStockIssuance 6M 5M 4M 9M 8M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -10M -8M -2M -12M -4M
netCashProvidedByFinancingActivities 51M 65M -78 000 -4M 3M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-11-04 ET (fiscal 2025 q3)
2025 q2
2025-08-05 ET (fiscal 2025 q2)
2025 q1
2025-05-06 ET (fiscal 2025 q1)
2024 q4
2025-02-25 ET (fiscal 2024 q4)
2024 q3
2024-11-10 ET (fiscal 2024 q3)
2024 q2
2024-08-06 ET (fiscal 2024 q2)
2024 q1
2024-05-07 ET (fiscal 2024 q1)
2023 q4
2024-03-05 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-14 ET (fiscal 2023 q1)
2022 q4
2023-03-06 ET (fiscal 2022 q4)
2022 q3
2022-11-05 ET (fiscal 2022 q3)
2022 q2
2022-08-07 ET (fiscal 2022 q2)
2022 q1
2022-05-06 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-05-18 11:00 ET
Orthofix to Participate in Upcoming Investor Conferences
2026-05-06 ET
Orthofix Expands Pediatric Limb Reconstruction Portfolio with New FITBONE™ Innovation at POSNA 2026 Annual Meeting
2026-05-05 ET
Orthofix Reports First Quarter 2026 Results Highlighting Steady Execution Following Spine Commercial Channel Actions; Reaffirms Full-Year 2026 Financial Guidance
2026-04-21 ET
Orthofix to Report First Quarter 2026 Financial Results
2026-04-09 ET
Orthofix Realigns Spine Leadership to Strengthen Focus and Execution
2026-02-24 ET
Orthofix Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance
2026-02-10 12:00 ET
Orthofix to Participate in Upcoming Investor Conferences
2026-02-03 12:00 ET
Orthofix to Report Fourth Quarter and Full-Year 2025 Financial Results
2025-11-04 ET
Orthofix Reports Third Quarter 2025 Financial Results
2025-10-15 ET
Orthofix to Participate in Upcoming Investor Conferences
2025-10-14 ET
Orthofix to Report Third Quarter 2025 Financial Results
2025-08-05 ET
Orthofix Reports Second Quarter 2025 Financial Results
2025-07-16 ET
Orthofix to Participate at Canaccord Genuity 45th Annual Growth Conference
2025-07-15 ET
Orthofix to Report Second Quarter 2025 Financial Results
2025-06-17 ET
Orthofix Announces Global Commercial Launch of the TrueLok Elevate Transverse Bone Transport System
2025-05-06 ET
Orthofix Reports First Quarter 2025 Financial Results
2025-04-15 ET
Orthofix to Report First Quarter 2025 Financial Results
2025-03-19 ET
Orthofix Receives 510(k) Clearance and CE Mark for TrueLok Elevate Transverse Bone Transport System
2025-03-12 ET
Orthofix Announces Appointment of Vickie Capps to Board of Directors
2025-03-03 ET
Orthofix to Participate in the 37th Annual Roth Conference
2025-02-25 ET
Orthofix Reports Fourth Quarter and Full-Year 2024 Results and Provides 2025 Financial Guidance
2025-02-17 ET
Orthofix to Participate in the Canaccord Genuity 2025 Musculoskeletal Conference
2025-01-28 ET
Orthofix to Report Fourth Quarter and Full-Year 2024 Financial Results
2024-11-12 ET
Orthofix to Participate in Upcoming Investor Conferences
2024-11-07 12:05 ET
Orthofix Announces New Term Loan
2024-11-07 12:05 ET
Orthofix Reports Third Quarter 2024 Results, Reiterates Full-Year 2024 Financial Guidance, and Introduces New Three-Year Financial Targets
2024-10-21 11:00 ET
Orthofix to Participate in Stifel 2024 Healthcare Conference
2024-10-10 11:00 ET
Orthofix to Report Third Quarter 2024 Financial Results
2024-09-30 16:06 ET
SHAREHOLDER DEADLINE: Orthofix Medical (OFIX) Investors Are Reminded of Deadline in Securities Action
2024-09-23 11:00 ET
Orthofix Highlights New Products and Announces Presentation of Data Supporting the Adjunct Use of Bone Growth Therapy for Lumbar Spine Fusion at North American Spine Society Annual Meeting
2024-09-23 10:06 ET
SHAREHOLDER DEADLINE: Orthofix Medical (OFIX) Investors Are Reminded of Deadline in Securities Action
2024-09-19 20:36 ET
SHAREHOLDER DEADLINE: Orthofix (OFIX) Investors Are Reminded of Deadline in Securities Action
2024-09-17 16:36 ET
ATTENTION Orthofix Medical, Inc. (OFIX) Shareholders: Securities Fraud Lawsuit Filed Against Orthofix Medical, Inc. (OFIX)
2024-08-06 11:03 ET
Orthofix Reports Second Quarter 2024 Results and Raises Full-Year 2024 Financial Guidance
2024-07-17 11:00 ET
Orthofix to Participate in Canaccord Genuity's 44th Annual Growth Conference
2024-07-16 11:00 ET
Orthofix Names Stephanie Walsh Chief Human Resources Officer
2024-07-09 11:00 ET
Orthofix Announces 510(k) Clearance and First Implant of Fitbone Transport and Lengthening System
2024-07-09 11:00 ET
Orthofix to Report Second Quarter 2024 Financial Results
2024-06-24 11:00 ET
Michael Finegan Named Chair of the Orthofix Board of Directors
2024-06-18 11:00 ET
Aviva McPherron Joins Orthofix as President of Global Operations and Quality
2024-06-11 11:00 ET
Orthofix Names Julie Dewey Chief Investor Relations and Communications Officer; Max Reinhardt Begins as President of Global Spine
2024-05-23 11:00 ET
Orthofix Names Max Reinhardt President of Global Spine Business
2024-05-16 11:00 ET
Orthofix Wins “Best Patient Experience Solution” Award in 2024 MedTech Breakthrough Awards Program
2024-05-09 11:00 ET
Orthofix Announces FDA 510(k) Clearance for the Rodeo Telescopic Nail
2024-05-07 12:00 ET
Orthofix Reports First Quarter 2024 Results
2024-04-23 11:00 ET
Orthofix Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024
2024-04-16 11:00 ET
Orthofix Names Andres Cedron as New Chief Legal Officer
2024-03-18 11:00 ET
Lucas Vitale Joins Orthofix as Chief People and Business Operations Officer
2024-03-05 21:03 ET
Orthofix Reports Fourth Quarter and Full Year 2023 Results
2024-02-29 12:00 ET
Orthofix Announces New President for Bone Growth Therapies Business
2024-02-21 12:00 ET
Orthofix Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for March 5, 2024
2024-01-18 12:00 ET
Orthofix Announces Commercial Partnership with MRIguidance
2024-01-16 12:00 ET
Julie Andrews Begins as New Chief Financial Officer at Orthofix
2024-01-09 13:00 ET
Orthofix Medical Inc. Announces Preliminary 2023 Fourth Quarter and Full-Year Net Sales Results
2024-01-08 12:00 ET
Orthofix Provides Executive Management Business Update and Appoints Julie Andrews as Chief Financial Officer
2023-12-21 12:00 ET
Orthofix Announces Publication of New Data Supporting Use of PEMF Stimulation in Lumbar Spine Fusion Procedures for Patients at Risk of Pseudarthrosis
2023-12-12 12:00 ET
Orthofix Announces Agreement with Engine Capital and Appointment of Three New Independent Directors to Further Advance Position as Leading Global Spine and Orthopedics Company
2023-11-29 12:00 ET
Orthofix Announces Publication in The Spine Journal of Five-Year Data for the M6-C Artificial Cervical Disc
2023-11-28 12:00 ET
Orthofix Names Massimo Calafiore as President and Chief Executive Officer
2023-11-08 21:07 ET
Orthofix Reports Third Quarter 2023 Results
2023-11-06 12:00 ET
Orthofix Announces Full Commercial Launch of the WaveForm L Interbody System for Lateral Lumbar Fusion Procedures
2023-10-18 11:00 ET
Orthofix Schedules Third Quarter Earnings Release and Conference Call for November 8, 2023
2023-10-12 11:00 ET
Orthofix Announces 510k Clearance and Full Commercial Launch of OsteoCove, an Advanced Bioactive Synthetic Graft for use in Spine and Orthopedic Procedures
2023-09-20 11:00 ET
Orthofix Announces First Patient Procedures and Full Commercial Launch of the Galaxy Fixation Gemini System and Expanded Sterile Kit Offerings for Orthopedic Trauma Procedures
2023-09-12 11:03 ET
Orthofix Announces Leadership Changes
2023-08-31 12:00 ET
Orthofix to Participate in Morgan Stanley Healthcare Conference
2023-08-28 11:00 ET
Orthofix Announces First Cases and Full Commercial Launch of the 7D FLASH Navigation System Percutaneous Module 2.0 for Minimally Invasive Surgery
2023-08-23 11:00 ET
Orthofix Medical to Host Investor Day on September 20, 2023
2023-08-08 20:08 ET
Orthofix Reports Second Quarter 2023 Results and Raises Revenue and Adjusted EBITDA Guidance
2023-07-25 11:00 ET
Orthofix Schedules Second Quarter Earnings Release and Conference Call for August 8, 2023, and Announces Participation in Upcoming Investor Conference
2023-06-28 11:00 ET
Orthofix Introduces New Phantom and Tornado Hinges for TrueLok Ring Fixation Systems
2023-06-20 20:01 ET
Orthofix Announces Changes to Board of Directors
2023-06-19 11:00 ET
Orthofix Announces the Full Commercial Launch of WaveForm A 3D Printed Anterior Lumbar Interbody
2023-06-01 11:00 ET
Orthofix Announces First Presentation of Seven-Year Outcome Data for the M6-C Artificial Cervical Disc With Other Clinical and Scientific Abstracts at the ISASS Annual Meeting
2023-05-09 20:01 ET
Orthofix Reports First Quarter 2023 Results
2023-05-04 11:00 ET
MedTech Breakthrough Recognizes STIM onTrack for Bone Growth Therapy as Best Patient Engagement Mobile App
2023-04-26 20:01 ET
Orthofix Medical Schedules First Quarter Earnings Release and Conference Call for May 9, 2023
2023-04-25 11:00 ET
Orthofix Expands Solutions for Minimally Invasive Spine Procedures with the Full Commercial Launch of Two Access Retractor Systems
2023-03-07 12:00 ET
Orthofix Announces More Than 5,000 Fitbone Intramedullary Limb-lengthening Devices Implanted Worldwide to Date and Over Twenty Years of Clinical History
2023-03-06 21:01 ET
Orthofix Medical Reports Orthofix and SeaSpine Fourth Quarter and Full-Year 2022 Results
2023-03-03 12:00 ET
Orthofix Medical to Hold Analyst Teach-In Meeting on March 13, 2023
2023-02-22 21:05 ET
Orthofix Medical to Present at Canaccord Genuity 2023 Musculoskeletal Conference
2023-02-21 21:05 ET
Orthofix Medical Schedules Fourth Quarter Earnings Release and Conference Call for March 6, 2023
2023-01-26 12:00 ET
Orthofix Announces Full Commercial Launch and First Patient Cases of Mariner Deformity System
2023-01-09 12:00 ET
Orthofix Medical Inc. Announces Preliminary SeaSpine and Orthofix 2022 Fourth Quarter and Full-Year Net Sales Results
2023-01-04 21:01 ET
Orthofix and SeaSpine Announce Completion of Merger of Equals to Create a Leading Global Spine and Orthopedics Company
2022-12-22 12:00 ET
Orthofix Announces Publication of Data Demonstrating the Clinical Benefits of Trinity Elite Cellular Bone Allograft in Lumbar Fusion Procedures
2022-11-18 12:00 ET
Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing
2022-11-18 12:00 ET
Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing
2022-11-10 12:00 ET
Orthofix Medical Announces Participation in Upcoming Stifel Healthcare Conference
2022-11-03 11:00 ET
Orthofix Reports Third Quarter 2022 Results
2022-10-25 11:00 ET
Orthofix Medical Schedules Third Quarter Earnings Release and Conference Call for November 3, 2022
2022-10-13 11:00 ET
Orthofix Announces First Patient Implants with Legacy Demineralized Bone Matrix for Spine, Pelvic and Extremities Procedures
2022-10-12 11:00 ET
Orthofix and MTF Biologics Recognized with 2022 Spine Technology Award for Virtuos Lyograft – a First-of-Its-Kind, Shelf-Stable and Complete Autograft Substitute for Spine and Orthopedic Procedures
2022-10-11 10:05 ET
Orthofix Announces Preliminary Third Quarter and Year-To-Date 2022 Net Sales Results
2022-10-11 10:00 ET
Orthofix and SeaSpine to Combine in Merger of Equals to Create Leading Global Spine and Orthopedics Company
2022-10-11 10:00 ET
Orthofix and SeaSpine to Combine in Merger of Equals to Create Leading Global Spine and Orthopedics Company
2022-10-10 11:00 ET
Orthofix Announces Presentation of Long-Term Evidence Highlighting the Clinical Management of Cervical Disc Arthroplasty at North American Spine Society Annual Meeting
2022-09-14 11:00 ET
Orthofix Medical Announces Participation in Upcoming Sidoti Virtual Investor Conference
2022-08-05 11:00 ET
Orthofix Reports Second Quarter 2022 Results
2022-08-02 11:00 ET
Orthofix Medical and CGBio Announce Strategic Partnership Agreement for Novosis rhBMP-2 Bone Graft Solutions
2022-07-27 20:05 ET
Orthofix Medical Schedules Second Quarter Earnings Release and Conference Call for August 5, 2022
2022-07-26 11:00 ET
Orthofix Announces First Clinical Use of Virtuos Lyograft – a First-of-Its-Kind, Shelf-Stable and Complete Autograft Substitute for Spine and Orthopedic Procedures
2022-07-13 11:00 ET
Orthofix Medical and LimaCorporate Announce Partnership to Provide Solution for Patients with High Hip Dislocation for the US Market
2022-05-31 11:00 ET
Orthofix M6-C Artificial Cervical Disc IDE Study Data to be Presented at ISASS Demonstrates Continued Statistically Significant Benefits at Five Years
2022-05-16 11:00 ET
Orthofix Medical Announces Participation in Upcoming UBS Global Healthcare Conference
2022-05-06 11:00 ET
Orthofix Reports First Quarter 2022 Results
2022-05-04 11:00 ET
FDA Grants PMA for the AccelStim Bone Growth Stimulation Device — Expanding Orthofix’s Portfolio of Market-Leading Bone Healing Therapy Solutions
2022-05-03 11:00 ET
Orthofix and MTF Biologics Expand Partnership Agreement
2022-04-28 11:00 ET
Orthofix Medical Schedules First Quarter Earnings Release and Conference Call for May 6, 2022
2022-04-08 11:00 ET
Orthofix Announces New Business Unit President
2022-03-16 11:00 ET
Orthofix Announces FDA Clearance and First Patient Cases With the TrueLok EVO Ring Fixation System
2022-02-25 12:00 ET
Orthofix Reports Fourth Quarter and Fiscal Year 2021 Results
2022-02-22 12:00 ET
Orthofix Expands Synthetic Bone Growth Offerings with Full Market Launch of Opus BA – a Bioactive Solution for Spine Procedures
2022-02-10 12:00 ET
Orthofix Medical Schedules Fourth Quarter and Full Year Earnings Release and Conference Call for February 25, 2022
2022-01-19 12:00 ET
Orthofix Announces Investment and Partnership with nView medical, Developer of Novel Imaging and Guidance Systems
2022-01-10 12:00 ET
Orthofix Announces Preliminary 2021 Fourth Quarter and Full Year Net Sales Results
2021-12-14 12:00 ET
Orthofix Announces Appointment of Thomas A. West to Board of Directors
2021-11-05 11:00 ET
Orthofix Reports Third Quarter 2021 Results
2021-11-03 20:05 ET
Orthofix Announces Participation in Upcoming Credit Suisse and Stifel Healthcare Conferences
2021-10-27 20:05 ET
Orthofix Schedules Third Quarter Earnings Release and Conference Call for November 5, 2021
2021-09-29 11:00 ET
Orthofix Provides Business Update
2021-09-27 11:00 ET
Orthofix Announces Milestone − More Than 60,000 M6-C Artificial Cervical Discs Implanted Worldwide
2021-09-23 11:00 ET
Orthofix Announces Appointment of Wayne Burris to Board of Directors
2021-09-21 11:00 ET
Orthofix Announces Full Market Launch of Opus Mg Set – a Magnesium-based Settable Bone Void Filler for Orthopedic Procedures
2021-09-20 11:00 ET
Orthofix Announces Participation in Upcoming Sidoti Virtual Investor Conference
2021-09-01 11:00 ET
Orthofix Announces First US Pediatric Implant of the Fitbone Limb-Lengthening System
2021-08-06 11:00 ET
Orthofix Reports Second Quarter 2021 Results
2021-08-02 11:00 ET
Orthofix Announces First Patient Implant in the M6-C Artificial Cervical Disc Two-Level IDE Study
2021-07-28 20:30 ET
Orthofix Schedules Second Quarter Earnings Release and Conference Call for August 6, 2021
2021-07-28 11:00 ET
Orthofix Announces US Launch and First Patient Implants with New fiberFUSE Strip – An Advanced Fiber Bone-Graft Solution Containing Cancellous Bone
2021-07-12 11:00 ET
Publication of Data Shows High Fusion Rate in Patients Treated with PEMF Therapy Using the Orthofix SpinalStim Device
2021-06-29 11:00 ET
Orthofix Announces U.S. Launch and First Patient Implant of 3D-Printed FORZA Titanium PLIF Spacer System with Nanovate Technology
2021-06-11 11:01 ET
Orthofix Announces Participation in Upcoming JMP Securities Life Sciences Conference
2021-05-27 20:01 ET
Orthofix Announces Participation in Upcoming Jefferies Virtual Healthcare Conference
2021-05-19 11:00 ET
Orthofix Renews Sponsorship of Olympic Gold Medalist and Spine Patient Laura Wilkinson
2021-05-17 11:00 ET
Orthofix Announces US and European Full Market Launch of OSCAR PRO System for Removal of Cement During Complex Joint Revision Surgeries
2021-05-13 11:00 ET
Orthofix M6-C Artificial Cervical Disc IDE Study Three- and Four-Year Data to be Presented at ISASS
2021-05-10 11:00 ET
Orthofix Announces FDA Clearance of the OrthoNext Digital Platform for the JuniOrtho Plating System
2021-04-30 11:00 ET
Orthofix Reports First Quarter 2021 Results
2021-04-28 11:00 ET
Orthofix Announces Exclusive US License for IGEA’s Bone and Joint Stimulation Devices
2021-04-22 20:01 ET
Orthofix Schedules First Quarter Earnings Release and Conference Call for April 30, 2021
2021-04-22 11:00 ET
Orthofix Announces FDA Clearance and First Patient Implant of the 3D-Printed FORZA Titanium TLIF Spacer System with Nanovate Technology
2021-04-07 11:00 ET
Orthofix Announces Board Chair Transition
2021-04-05 11:00 ET
Orthofix Announces FDA Clearance and Initial Patient Implant of the Company’s First 3D-Printed Titanium Cervical Spacer System with Nanovate Technology
2021-03-10 12:00 ET
Orthofix Launches Nationwide Recycling Program to Improve Sustainability
2021-02-26 12:00 ET
Orthofix Reports Fourth Quarter and Fiscal Year 2020 Results
2021-02-11 21:40 ET
Orthofix to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference on February 19
2021-02-11 21:35 ET
Orthofix Schedules Fourth Quarter and Full Year Earnings Release and Conference Call for February 26, 2021
2021-02-11 12:00 ET
Orthofix Announces US and European Full Market Launch of FITBONE Limb-Lengthening System
2021-01-28 12:00 ET
Orthofix Announces Publication of Two-Year Data from the M6-C Artificial Cervical Disc Study
2021-01-12 12:00 ET
Orthofix Announces Preliminary 2020 Fourth Quarter and Full Year Net Sales Results
2021-01-06 12:00 ET
Orthofix Announces Participation in Upcoming J.P. Morgan Healthcare and ICR Westwicke Conferences
2020-11-10 12:00 ET
Orthofix to Present at the Stifel 2020 Virtual Healthcare Conference on November 16
2020-11-05 12:00 ET
Orthofix Reports Third Quarter 2020 Results
2020-10-27 20:15 ET
Orthofix Schedules Third Quarter 2020 Earnings Release and Conference Call for November 5, 2020
2020-10-07 11:00 ET
Orthofix Launches O-GENESIS Graft Delivery System and New Hydrated, Ready-to-Use AlloQuent Structural Allograft Q-PACK
2020-10-06 11:00 ET
Orthofix Announces Presentation of Clinical and Scientific Abstracts During the North American Spine Society Annual Meeting
2020-10-01 11:00 ET
Orthofix FIREBIRD SI Fusion System Receives Additional FDA Clearance for Nanotechnology
2020-09-22 11:00 ET
Orthofix and Neo Medical Announce Partnership to Develop and Market Single-Use Spinal Solutions Focused on Improving Patient Outcomes
2020-09-14 11:00 ET
Paul Gonsalves Joins Orthofix as President of Global Extremities Business
2020-09-09 11:15 ET
FDA Advisory Panel Recommends Pre-Market Clinical Evidence Requirement in Proposed Reclassification of Bone Growth Stimulators
2020-08-06 11:00 ET
Orthofix Reports Second Quarter 2020 Results
2020-08-03 20:03 ET
Orthofix to Present at the Canaccord Genuity Growth Conference on August 13
2020-07-27 11:00 ET
Orthofix Schedules Second Quarter 2020 Earnings Release and Conference Call for August 6, 2020
2020-07-20 11:00 ET
Orthofix Receives FDA Clearance and CE Mark for the JuniOrtho Plating System
2020-06-29 11:00 ET
Orthofix Announces FDA Clearance and First Patient Implants of FIREBIRD SI Fusion System for Low Back Pain
2020-06-08 20:15 ET
Orthofix Announces Election of Jason Hannon to Board of Directors
2020-05-28 20:03 ET
Orthofix to Present at the Jefferies 2020 Healthcare Conference on June 2
2020-05-26 12:00 ET
Orthofix Announces Sponsorship of Olympic Gold Medalist and Spine Patient Laura Wilkinson
2020-05-08 10:00 ET
Orthofix Reports First Quarter 2020 Results
2020-05-07 20:03 ET
Orthofix to Present at the Bank of America Securities Healthcare Conference on May 14
2020-04-30 20:19 ET
Orthofix Schedules First Quarter 2020 Earnings Release and Conference Call for May 8, 2020
2020-04-09 13:00 ET
Orthofix Announces Preliminary First Quarter 2020 Results and Provides Business Update
2020-03-26 11:00 ET
Orthofix Completes Acquisition of FITBONE Limb Lengthening System
2020-02-24 23:26 ET
Orthofix Announces Support for Continued FDA Class III Designation for Bone Growth Stimulators to Ensure Patient Safety and Therapy Efficacy
2020-02-24 21:03 ET
Orthofix Reports Fourth Quarter and Fiscal Year 2019 Financial Results
2020-02-14 12:00 ET
Orthofix Schedules Fourth Quarter and Fiscal 2019 Earnings Release and Conference Call for February 24, 2020
2020-02-13 12:00 ET
Orthofix Announces FDA Approval of STIM onTrack 2.1 Mobile App for Bone Growth Stimulators
2020-02-04 14:00 ET
Orthofix Announces Agreement to Acquire FITBONE Limb Lengthening System
2019-12-05 12:00 ET
Orthofix Names Kevin Kenny President of Global Spine Business
2019-11-01 11:00 ET
Orthofix Appoints Jon Serbousek as President and Chief Executive Officer
2019-10-28 20:01 ET
Orthofix Reports Third Quarter 2019 Results
2019-10-21 11:00 ET
Orthofix Schedules Third Quarter 2019 Earnings Release and Conference Call for October 28, 2019

SEC forms

Show financial reports only

SEC form 10
2026-05-05 11:03 ET
Orthofix Medical published news for 2026 q1
SEC form 8
2026-05-05 11:02 ET
Orthofix Medical published news for 2026 q1
SEC form 8
2026-05-05 11:02 ET
Orthofix Medical published news for 2026 q1
SEC form 8
2026-05-05 11:02 ET
Orthofix Medical published news for 2026 q1
SEC form 8
2026-04-09 11:02 ET
Orthofix Medical published news for 2026 q1
SEC form 8
2026-04-09 11:02 ET
Orthofix Medical published news for 2026 q1
SEC form 10
2026-02-24 07:04 ET
Orthofix Medical published news for 2025 q4
SEC form 8
2026-02-24 07:01 ET
Orthofix Medical published news for 2025 q4
SEC form 8
2026-02-24 07:01 ET
Orthofix Medical reported for 2025 q4
SEC form 8
2026-02-24 07:01 ET
Orthofix Medical published news for 2025 q4
SEC form 10
2025-11-04 09:01 ET
Orthofix Medical reported for 2025 q3
SEC form 8
2025-11-04 07:02 ET
Orthofix Medical published news for 2025 q3
SEC form 8
2025-11-04 07:02 ET
Orthofix Medical reported for 2025 q3
SEC form 8
2025-11-04 07:02 ET
Orthofix Medical published news for 2025 q3
SEC form 10
2025-08-05 11:05 ET
Orthofix Medical reported for 2025 q2
SEC form 8
2025-08-05 11:03 ET
Orthofix Medical published news for 2025 q2
SEC form 8
2025-08-05 11:03 ET
Orthofix Medical reported for 2025 q2
SEC form 8
2025-08-05 11:03 ET
Orthofix Medical published news for 2025 q2
SEC form 8
2025-06-20 13:00 ET
Orthofix Medical published news for 2025 q1
SEC form 10
2025-05-06 11:05 ET
Orthofix Medical reported for 2025 q1
SEC form 8
2025-05-06 11:03 ET
Orthofix Medical published news for 2025 q1
SEC form 8
2025-05-06 11:03 ET
Orthofix Medical reported for 2025 q1
SEC form 8
2025-05-06 11:03 ET
Orthofix Medical published news for 2025 q1
SEC form 10
2025-05-06 00:00 ET
Orthofix Medical reported for 2025 q1
SEC form 10
2025-02-25 12:08 ET
Orthofix Medical published news for 2024 q4
SEC form 10
2025-02-25 00:00 ET
Orthofix Medical published news for 2024 q4
SEC form 8
2025-02-25 00:00 ET
Orthofix Medical published news for 2024 q4
SEC form 8
2025-02-25 00:00 ET
Orthofix Medical reported for 2024 q4
SEC form 8
2025-02-25 00:00 ET
Orthofix Medical published news for 2024 q4
SEC form 10
2024-11-07 07:08 ET
Orthofix Medical published news for 2024 q3
SEC form 8
2024-11-07 07:06 ET
Orthofix Medical published news for 2024 q3
SEC form 8
2024-11-07 07:06 ET
Orthofix Medical published news for 2024 q3
SEC form 8
2024-11-07 07:06 ET
Orthofix Medical published news for 2024 q3
SEC form 10
2024-08-06 07:08 ET
Orthofix Medical reported for 2024 q2
SEC form 8
2024-08-06 07:06 ET
Orthofix Medical published news for 2024 q2
SEC form 8
2024-08-06 07:06 ET
Orthofix Medical published news for 2024 q2
SEC form 8
2024-08-06 07:06 ET
Orthofix Medical published news for 2024 q2
SEC form 10
2024-08-06 00:00 ET
Orthofix Medical published news for 2024 q2
SEC form 10
2024-05-07 08:06 ET
Orthofix Medical reported for 2024 q1
SEC form 8
2024-05-07 08:04 ET
Orthofix Medical published news for 2024 q1
SEC form 8
2024-05-07 08:04 ET
Orthofix Medical published news for 2024 q1
SEC form 8
2024-05-07 08:04 ET
Orthofix Medical published news for 2024 q1
SEC form 8
2024-05-07 08:04 ET
Orthofix Medical published news for 2024 q1
SEC form 10
2024-05-07 00:00 ET
Orthofix Medical published news for 2024 q1
SEC form 10
2024-03-05 16:06 ET
Orthofix Medical published news for 2023 q4
SEC form 8
2024-03-05 16:05 ET
Orthofix Medical published news for 2023 q4
SEC form 8
2024-03-05 16:05 ET
Orthofix Medical reported for 2023 q4
SEC form 8
2024-03-05 16:05 ET
Orthofix Medical published news for 2023 q4
SEC form 8
2024-03-05 16:05 ET
Orthofix Medical published news for 2023 q4
SEC form 10
2024-03-05 00:00 ET
Orthofix Medical published news for 2023 q4
SEC form 8
2024-01-09 00:00 ET
Orthofix Medical published news for 2023 q4
SEC form 8
2024-01-09 00:00 ET
Orthofix Medical published news for 2023 q4
SEC form 8
2024-01-09 00:00 ET
Orthofix Medical published news for 2023 q4
SEC form 8
2024-01-09 00:00 ET
Orthofix Medical reported for 2023 q4
SEC form 10
2023-11-08 16:15 ET
Orthofix Medical reported for 2023 q3
SEC form 8
2023-11-08 16:12 ET
Orthofix Medical published news for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Orthofix Medical published news for 2023 q3
SEC form 10
2023-08-08 16:28 ET
Orthofix Medical reported for 2023 q2
SEC form 6
2023-08-08 16:24 ET
Orthofix Medical published news for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Orthofix Medical published news for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Orthofix Medical published news for 2023 q2
SEC form 6
2023-06-21 07:01 ET
Orthofix Medical published news for 2023 q1
SEC form 6
2023-06-20 16:02 ET
Orthofix Medical published news for 2023 q1
SEC form 6
2023-06-15 16:58 ET
Orthofix Medical published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Orthofix Medical published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Orthofix Medical published news for 2023 q1
SEC form 6
2023-04-07 17:00 ET
Orthofix Medical published news for 2023 q1
SEC form 6
2023-03-13 07:29 ET
Orthofix Medical published news for 2022 q4
SEC form 10
2023-03-06 16:11 ET
Orthofix Medical published news for 2022 q4
SEC form 6
2023-03-06 16:09 ET
Orthofix Medical published news for 2022 q4
SEC form 10
2023-03-06 00:00 ET
Orthofix Medical published news for 2022 q4
SEC form 8
2023-03-06 00:00 ET
Orthofix Medical reported for 2022 q4
SEC form 6
2023-02-10 19:03 ET
Orthofix Medical published news for 2022 q4
SEC form 6
2023-01-09 07:14 ET
Orthofix Medical published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Orthofix Medical reported for 2022 q4
SEC form 6
2023-01-05 06:08 ET
Orthofix Medical published news for 2022 q4
SEC form 6
2023-01-04 16:31 ET
Orthofix Medical published news for 2022 q4
SEC form 6
2022-12-27 17:26 ET
Orthofix Medical published news for 2022 q3
SEC form 6
2022-12-05 17:24 ET
Orthofix Medical published news for 2022 q3
SEC form 6
2022-11-30 17:25 ET
Orthofix Medical published news for 2022 q3
SEC form 6
2022-11-18 21:51 ET
Orthofix Medical published news for 2022 q3
SEC form 10
2022-11-03 07:13 ET
Orthofix Medical reported for 2022 q3
SEC form 6
2022-11-03 07:08 ET
Orthofix Medical published news for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Orthofix Medical reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Orthofix Medical reported for 2022 q3
SEC form 6
2022-10-11 06:37 ET
Orthofix Medical published news for 2022 q3
SEC form 6
2022-10-11 06:29 ET
Orthofix Medical published news for 2022 q3
SEC form 8
2022-10-11 00:00 ET
Orthofix Medical published news for 2022 q3
SEC form 10
2022-08-05 07:34 ET
Orthofix Medical reported for 2022 q2
SEC form 6
2022-08-05 07:09 ET
Orthofix Medical published news for 2022 q2
SEC form 10
2022-08-05 00:00 ET
Orthofix Medical reported for 2022 q2
SEC form 8
2022-08-05 00:00 ET
Orthofix Medical reported for 2022 q2
SEC form 6
2022-06-07 07:36 ET
Orthofix Medical published news for 2022 q1
SEC form 10
2022-05-06 07:58 ET
Orthofix Medical reported for 2022 q1
SEC form 6
2022-05-06 07:57 ET
Orthofix Medical published news for 2022 q1
SEC form 10
2022-05-06 00:00 ET
Orthofix Medical reported for 2022 q1
SEC form 8
2022-05-06 00:00 ET
Orthofix Medical reported for 2022 q1
SEC form 6
2022-04-27 16:30 ET
Orthofix Medical published news for 2022 q1
SEC form 6
2022-04-08 07:19 ET
Orthofix Medical published news for 2022 q1
SEC form 10
2022-02-25 08:21 ET
Orthofix Medical published news for 2021 q4
SEC form 6
2022-02-25 08:15 ET
Orthofix Medical published news for 2021 q4
SEC form 10
2022-02-25 00:00 ET
Orthofix Medical published news for 2021 q4
SEC form 8
2022-02-25 00:00 ET
Orthofix Medical published news for 2021 q4
SEC form 6
2022-01-10 07:30 ET
Orthofix Medical published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Orthofix Medical published news for 2021 q4
SEC form 6
2021-12-14 07:30 ET
Orthofix Medical published news for 2021 q3
SEC form 10
2021-11-05 08:21 ET
Orthofix Medical published news for 2021 q3
SEC form 6
2021-11-05 08:15 ET
Orthofix Medical published news for 2021 q3
SEC form 10
2021-11-05 00:00 ET
Orthofix Medical published news for 2021 q3
SEC form 8
2021-11-05 00:00 ET
Orthofix Medical published news for 2021 q3
SEC form 6
2021-09-29 07:05 ET
Orthofix Medical published news for 2021 q2
SEC form 6
2021-09-23 08:00 ET
Orthofix Medical published news for 2021 q2
SEC form 10
2021-08-06 08:18 ET
Orthofix Medical published news for 2021 q2
SEC form 6
2021-08-06 08:10 ET
Orthofix Medical published news for 2021 q2
SEC form 10
2021-08-06 00:00 ET
Orthofix Medical published news for 2021 q2
SEC form 8
2021-08-06 00:00 ET
Orthofix Medical published news for 2021 q2
SEC form 6
2021-07-06 07:30 ET
Orthofix Medical published news for 2021 q2
SEC form 6
2021-06-21 16:34 ET
Orthofix Medical published news for 2021 q1
SEC form 10
2021-04-30 08:27 ET
Orthofix Medical published news for 2021 q1
SEC form 6
2021-04-30 08:20 ET
Orthofix Medical published news for 2021 q1
SEC form 10
2021-04-30 00:00 ET
Orthofix Medical published news for 2021 q1
SEC form 8
2021-04-30 00:00 ET
Orthofix Medical published news for 2021 q1
SEC form 6
2021-04-29 17:02 ET
Orthofix Medical published news for 2021 q1
SEC form 6
2021-04-07 07:30 ET
Orthofix Medical published news for 2021 q1
SEC form 10
2021-02-26 08:37 ET
Orthofix Medical published news for 2020 q4
SEC form 6
2021-02-26 08:22 ET
Orthofix Medical published news for 2020 q4
SEC form 6
2021-01-29 16:14 ET
Orthofix Medical published news for 2020 q4
SEC form 6
2021-01-12 07:20 ET
Orthofix Medical published news for 2020 q4
SEC form 10
2020-11-05 08:16 ET
Orthofix Medical published news for 2020 q3
SEC form 6
2020-11-05 08:00 ET
Orthofix Medical published news for 2020 q3